ENGELHART-COMMODITIES
10.6.2024 08:58:29 CEST | Business Wire | Press release
Engelhart Commodities Trading Partners, a global commodities trading business, is delighted to announce that it has agreed terms to acquire Trailstone, a global energy and technology company, from Riverstone.
Completion of the acquisition, which remains subject to regulatory approval, is expected to occur in Q3, 2024.
The deal is a significant event for both companies, as it represents a shared commitment to ensuring the success of the clean energy transition. The transaction not only strengthens their trading and technological capabilities, but also generates value through active support of a sustainable future.
Trailstone is a global leader in the provision of risk management and optimization services to the owners and operators of renewable power generation assets, by utilising its expertise, analytics and proprietary software. It is also active in trading power, natural gas and environmental products across North America, Europe and Asia.
The team at Trailstone has also built a successful physical natural gas client business in North America, which provides storage, transportation and supply capabilities to serve its customers' growing optimization and risk management requirements.
The acquisition will combine the resources and expertise of two successful businesses and enable them to leverage their joint capabilities to enhance trading performance, grow their customer business and play a leading role in decarbonising the world’s energy matrix.
The acquisition is a pivotal part of Engelhart’s strategic plan to strengthen its global power and gas trading platform and technology capabilities and generate value through active participation in the clean energy transition.
Huw Jenkins, Engelhart CEO, says the acquisition is a clear signal of Engelhart’s commitment to the clean energy transition:
“Agreeing terms to acquire Trailstone is an important event in Engelhart’s long term strategy to grow our energy trading platform and enhance our technological capability to play a leading role in the clean energy transition. We have been impressed by the Trailstone team’s innovation in the renewables trading sector and we believe the acquisition and merger will be highly complementary for both businesses.”
John Redpath, CEO, Trailstone, says he’s excited about the potential that this acquisition unlocks:
“The acquisition by Engelhart is a big moment for the future of Trailstone. The access to permanent capital, and the complementary nature of our two organizations means we can grow our renewables and power & natural gas businesses and create even more value as part of the clean energy transition. I am proud of what we've created at Trailstone over the last ten years, not because it was easy but because it was hard. I am even more positive and excited about the future as we move forward as one business. I've been in the energy markets for 35 years, and I think the most interesting years of my career are ahead as we build this combined business.”
FOR EDITORS
- The acquisition has been agreed but remains subject to regulatory approval.
- Latham & Watkins LLP acted as legal advisors to Riverstone and Trailstone. Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisers to Engelhart Commodities Trading Partners.
- Engelhart is a global commodity trading company founded in 2013, with ~180 staff across offices in London, Geneva, Houston, Stamford, Singapore, Shanghai and Beijing.
- Engelhart trades energy (power and gas, and oil) and is also active in agricultural/soft commodities, freight, and the innovative area of ‘risk premia’.
- Engelhart is owned by the same partner group that also controls BTG Pactual, the largest investment bank in Latin America.
- Trailstone is a global energy and technology trading company, operating at the intersection of renewable and conventional power. Trailstone provides a best-in-class service to help manage the intermittency of renewable power generation for asset owners, operators and grid infrastructure. Trailstone also offers tech-enabled risk management and asset management optimization solutions for renewables assets across Europe, Japan and the United States. Trailstone was founded in 2013 and has ~275 staff across offices in Europe, North America, and Japan, with its primary offices in London, Austin, and Berlin.
- Engelhart will acquire Trailstone from Riverstone LLC, the private equity fund that was its primary shareholder, subject to regulatory approval.
- Huw Jenkins will be the CEO of the new combined business; John Redpath will be Deputy CEO.
- No decision has yet been made on future naming and branding. For now, just use ‘Engelhart Commodities Trading Partners’, ‘Engelhart’ or ‘Trailstone’ or ‘the combined business’ to describe the relevant parties.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240609840553/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
